Inventia Life Science

Sign in

Inventia Life Science and BioLamina partner to advance cell matrices for complex 3D cell models

24th August, 2021

Sydney, Australia

Inventia Life Science, together with BioLamina AB, a Swedish biotechnology company leading in matrix biology and cell culture-based research, have entered into a partnership in order to supply 3D cell culture scaffolds, compatible with the RASTRUM™ platform, containing human recombinant laminin proteins (Biolaminin®). In this partnership, Inventia Life Science will now offer BioLamina’s extensive range of Biolaminin® products to be incorporated into the prevalidated library of RASTRUM™ Matrices, recapitulating the key motifs found in the native tissue of various cell types.

Laminins, important proteins found in cells’ and tissues’ extracellular matrix (ECM) and microenvironment, are typically required by cells for differentiation, migration and cellular adhesion. By including laminins in in vitro cellular models, researchers have not only been able to mimic the native ECM of various tissues, but also study the role of different laminin isoforms in disease progression and drug resistance mechanisms.

“The partnership with Inventia Life Science is an important step in our ambition to demonstrate the roles of laminins in complex cellular assays. We strive to improve the quality and reliability of 3D cell culture by adding biorelevant Biolaminin® for tissue authentic cell responses. The RASTRUM™ platform adds significant customer value since it enables an automated workflow. We look forward to pursue the advancements that this collaboration can bring,” says Dr. Therese Kallur, Director of Business Development at BioLamina AB.

RASTRUM™ Matrices will now incorporate Biolamina’s human recombinant laminin proteins

This new partnership aims to provide next generation complex 3D cell models incorporating BioLamina’s experience and product portfolio, which has already proved to be of high interest to many researchers, particularly those working in oncology settings. The production of these laminin-containing 3D models can now be conducted in a highly reproducible manner, while also being significantly boosted by the automated and high-throughput capabilities of the renowned RASTRUM™ 3D cell culture platform.

“A physiologically relevant matrix environment is crucial for our RASTRUM™ 3D cell models to recapitulate various cellular behaviours and phenotypes. BioLamina’s Biolaminins® enable our RASTRUM™ Matrices to better mimic in vivo extracellular-matrix microenvironments in a reproducible and tissue specific manner,” says Dr. Robert Utama, Lead Product Manager of Inventia Life Science.

To learn more, please contact:
Inventia Life Science
Dr. Duyen Nguyen
Email: duyen.nguyen@inventia.life
www.inventia.life

BIOLAMINA AB
Dr. Therese Kallur
E-mail: therese.kallur@biolamina.com or communications@biolamina.com
www.biolamina.com

About Inventia Life Science

Inventia Life Science is a fast-growing biotech start-up based in Sydney, Australia, that is revolutionising cancer research, drug discovery and regenerative medicine. The award-winning RASTRUM™ cell culture platform has already been adopted in leading medical research institutes, biotechnology and pharmaceutical companies which are creating printed 3D tissue mimics that model real biology.

About BioLamina AB

BioLamina AB is a Swedish biotechnology company built on a scientific foundation with a legacy in matrix biology and cell culture-based research. Our flagship products, our biorelevant human recombinant laminin isoforms, Biolaminin®, are defined cell culture matrices that successfully imitate the natural, cell-specific cell-matrix interaction in the cell culture dish, allowing the cells to thrive and maintain their function. Our products are a powerful resource for scientists working with stem cells and primary cells both within basic research as well as in regenerative medicine companies with focus on cell therapy applications.

Inventia Life Science is a fast-growing biotechnology startup company based in Sydney, Australia, that is accelerating biomedical research and drug discovery